Anatomy & Cell Biology. Aug/31/2016; 49(3): 189-198

Published online Sep/28/2016

PMID: 27722012

PMC: 5052228

doi: 10.5115/acb.2016.49.3.189

Rhus verniciflua Stokes attenuates cholestatic liver cirrhosis-induced interstitial fibrosis via Smad3 down-regulation and Smad7 up-regulation

Young-Gil Jeong+4 authors

Abstract

Cholestatic liver cirrhosis (CLC) eventually proceeds to end-stage liver failure by mediating overwhelming deposition of collagen, which is produced by activated interstitial myofibroblasts. Although the beneficial effects of Rhus verniciflua Stokes (RVS) on various diseases are well-known, its therapeutic effect and possible underlying mechanism on interstitial fibrosis associated with CLC are not elucidated. This study was designed to assess the protective effects of RVS and its possible underlying mechanisms in rat models of CLC established by bile duct ligation (BDL). We demonstrated that BDL markedly elevated the serological parameters such as aspartate aminotransferase, alanine transaminase, total bilirubin, and direct bilirubin, all of which were significantly attenuated by the daily uptake of RVS (2 mg/kg/day) for 28 days (14 days before and after operation) via intragastric route. We observed that BDL drastically induced the deterioration of liver histoarchitecture and excessive deposition of extracellular matrix (ECM), both of which were significantly attenuated by RVS. In addition, we revealed that RVS inhibited BDL-induced proliferation and activation of interstitial myofibroblasts, a highly suggestive cell type for ECM production, as shown by immunohistochemical and semi-quantitative detection of α-smooth muscle actin and vimentin. Finally, we demonstrated that the anti-fibrotic effect of RVS was associated with the inactivation of Smad3, the key downstream target of a major fibrogenic cytokine, i.e., transforming growth factor β (TGF-β). Simultaneously, we also found that RVS reciprocally increased the expression of Smad7, a negative regulatory protein of the TGF-β/Smad3 pathway. Taken together, these results suggested that RVS has a therapeutic effect on CLC, and these effects are, at least partly, due to the inhibition of liver fibrosis by the downregulation of Smad3 and upregulation of Smad7.

Introduction

Cholestatic liver cirrhosis (CLC) is one of the major causative factors for the development of liver fibrosis worldwide [1]. Many researchers are trying to understand the pathophysiologic mechanisms of ongoing liver fibrosis because CLC produces imponderable socio-economical costs [2]. Liver fibrosis is known as the pathologic condition involving excessive production and deposition of extracellular matrix (ECM) that originates from a wide variety of liver parenchymal cells including hepatic stellate cells (HSC), hepatocytes, endothelial cells, and cholangiocytes [3 4 5]. Following hepatic damage, transforming growth factor-β (TGF-β), a master inflammatory/fibrogenic cytokine, is released from infiltrating macrophages. Upon the stimulation by TGF-β, Smad3 is phosphorylated, translocate to the nucleus, and start to exert the transcription activity [6]. While the Smad3 and the Smad7, a major negative regulatory protein, keeps balance, breakdown of balance between Smad3 and Smad7 stimulates the parenchymal cells and induces their transdifferentiation into myofibroblasts [7 8 9]. Subsequently, ECM starts to accumulate in the interstitial space, resulting the progressive and irreversible substitution of normal parenchyma by scar tissue [10 11].

Based on the notion that chronic inflammation essentially precedes the development of liver fibrosis, plant extracts that exert anti-inflammatory property have been empirically used for treating patients with various liver diseases in Asian countries [12]. Among them, Rhus verniciflua Stokes (RVS) has been traditionally used as a food supplement or a pharmaceutical in Korea and China [13]. Recent studies have revealed that RVS has various biological properties including antioxidant, antiobesity, antioncogenic, tumoricidal, and anti-inflammatory activities [14 15 16 17 18].

Previous report suggested that RVS shows protective activity in mice models of liver injury established by the administration of carbon tetrachloride [19]. This study focused on the antioxidant property of RVS as a therapeutic mechanism. A recent study demonstrated that butein, a major constituent of RVS, could inhibit ethanol-induced activation of HSC through the TGF-β signaling pathways [20]. Taken together, these results imply that RVS may be useful as a protective agent against different types of liver injuries. However, the roles of RVS in CLC-associated interstitial fibrosis have not been completely understood. The aim of this study was to assess the potential protective effects of RVS and unveil its possible underlying mechanisms in an in vivo model of CLC. Herein, we used a rat model of bile duct ligation (BDL) and focused on the involvement of the Smad pathway, a major downstream signaling mediator of TGF-β, as a potential modulatory target of RVS.

Materials and Methods

Preparation of RVS extracts

RVS extract was supplied by Lifetree Biotech Co., Ltd. (Suwon, Korea). The extract was prepared as described previously [21 22]. In brief, the timber of RVS was harvested in Wonju, Gangwon-do, South Korea, and was cut into 11×1×0.2-cm-sized pieces. These pieces were mixed with water (1:10, w/v) and then eluted with boiling water at 90–110℃ for 4 hours. The extract was concentrated to 15% solid content. Next, this concentrated extract was diluted with an equal volume of dextrin, followed by drying using spray-drying method. Urushiol, an allergenic constituent of RVS, was extracted. The urushiol-free RVS extract was authenticated by Korea Advanced Food Research Institute (KAFRI, Seoul, Korea).

Animals

All experiments with rats were acknowledged and regulated by the Institutional Animal Care and Use Committee (IACUC; approved protocol number: P-16-05-A-01) of the Konyang University (Daejeon, Korea). The 8-week-old male Sprague-Dawley rats (n=36; body weight, 185–200 g) were purchased from Samtako (Osan, Korea). The rats were acclimated in an environmentally controlled room at 23±2℃ with a 60±10% relative humidity in a 12-hour light/dark cycle, and they had free access to water and food. All experiments were conducted in accordance with the "Guide for the Care and Use of Laboratory Animals" (National Institutes of Health publication 8th edition, 2011).

Experimental design

The rats were randomly divided into the following groups (n=12 per group): sham-surgery (SHAM), BDL, and BDL with RVS-treatment (BDL+RVS) groups. For the BDL+RVS group, RVS (2 mg/kg/day) diluted in distilled water was administered by intragastric route for 28 days (14 days before and after BDL operation). For the BDL group, distilled water as a vehicle was given for 14 days before and after BDL operation. The group of rats receiving laparotomy without ligation of the bile duct was designated as SHAM group. On postoperative day (POD) 14, all the rats were weighed and sacrificed. The livers were removed and some of the tissues were frozen for protein determinations. The remaining tissues were fixed with formalin for histological study. Arterial blood was collected from abdominal aorta for serological assay.

Bile duct ligation

Common bile ducts of each rat were surgically ligated in accordance with the method of Tag et al. [23]. In brief, the rats were anesthetized with a 1:1 mixture (0.2 ml/kg each) of zoletil (Virbac Laboratories, Carros, France) and xylazine (Kepro, Deventer, The Netherlands). Following laparotomy, common bile duct was isolated and completely occluded with 4-0 black silk. Then, the surgical wound was closed with suture, and the rats were allowed to recover in home cages until they were fully awake and active.

Serological assay

Following the collection of arterial blood, sera were obtained by centrifuge. The sera were stored at −70℃ until assayed. The levels of total bilirubin (tBil), direct bilirubin (dBil), aspartate transaminase (AST), and alanine transaminase (ALT) were measured with DRI-CHEM 3000 colorimetric analyzer (Fujifilm, Tokyo, Japan).

Histology

The liver tissues obtained from the right lobe were fixed in 10% neutral buffered formalin and embedded in paraffin. Paraffin blocks were sliced into 5-µm-thick sections on a microtome (RM2255, Leica, Nussloch, Germany). Alterations in the histologic structures of the liver were examined by hematoxylin and eosin (H&E) and Masson's trichrome stain. H&E and Masson's trichrome staining were performed according to previous studies [24 25]. Two microscopic fields of tissue sections were randomly selected from each rat (n=12 in each group). These fields were photographed at 200× magnification by digital camera connected with light microscope (DM4, Leica) and examined by three blind observers. For assessment of fibrosis degree, the Knodell histology activity index (HAI) was slightly modified and utilized [26]. The following criteria were used in this study: 0, no fibrosis; 1, fibrous expansion of some portal tract with or without short fibrous septa; 2, fibrous expansion of most portal tracts with or without fibrous septa; 3, fibrous expansion of portal tract with occasional portal to portal bridging; 4, fibrous expansion of portal tracts with marked portal to portal as well as portal to central bridging; and 5, marked bridging (portal to portal and/or portal to central) with occasional nodules. Fibrotic areas were measured with the aid of image analysis system (ImageJ software, National Institutes of Health, Bethesda, MD, USA).

Immunofluorescence and immunohistochemistry

To measure the intrahepatic distribution of collagen-I (COL1) and α-smooth muscle actin (α-SMA)–immunopositive myofibroblasts, immunofluorescence (IF) and immunohistochemistry (IHC) were performed respectively. For each rat (n=12 in each group), two randomly selected liver sections were de-paraffinized in xylene, hydrated by immersion in baths featuring a decreasing ethanol gradient, and then washed in distilled water. Next, each section was incubated with primary antibodies that were diluted in blocking solution at a ratio of 1:200 for rabbit anti-COL1 (Santa Cruz Biotechnology, Dallas, TX, USA) and 1:100 for rabbit anti–α-SMA (Santa Cruz Biotechnology) for 24 hours at 4℃. After 3 washes in phosphate buffered saline (PBS), the sections incubated with anti-COL1 and anti–α-SMA were incubated with secondary antibodies containing Cy3-conjugated anti-rabbit IgG and biotinylated anti-rabbit IgG respectively, for 1 hour at room temperature. For IF, the slides were counterstained with mounting medium containing 4',6-diamidino-2-phenylindole and examined with a confocal laser scanning microscope (LSM700, Zeiss, Munchen, Germany). For IHC, the slides were further incubated with avidin-biotin complex solution for 1 hour at 36℃. The immunopositive regions turned dark brown after the addition of 3,3'-diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich, St. Louis, MO, USA) as a chromogen. After cessation of the reaction with DAB, the slides were counterstained with hematoxylin for nuclear staining and examined with a light microscope (Leica).

Western blot analysis

Total protein extraction and western blot analyses were performed as described in a previous study [27]. The liver tissue of each group was gently isolated and transferred to lysis buffer, and homogenized. Randomly chosen five tissue homogenates (n=5 in each group) were incubated with rabbit antibodies against α-SMA (1:1,000), vimentin (1:1,000), phosphorylated Smad3 (1:500), Smad3 (1:500), Smad7 (1:1,000), and glyceraldehyde 3-phosphate dehydrogenase (1:2,000) as primary antibodies. These antibodies were purchased from Santa Cruz Biotechnology. After subsequent incubation with horseradish peroxide–conjugated anti-rabbit IgG (1:1,000, Vector Laboratories, Burlingame, CA, USA) and 5 washes in PBS, the proteins in the polyvinylidene fluoride membranes were detected by a chemiluminescence detection system according to the manufacturer's instructions (ECL, GE Healthcare Life Sciences, Buckinghamshire, UK). The resulting bands were photographed with an imaging device Davinch-K (Davinch-K Corporation, Seoul, Korea). The intensities were quantified with an image analysis system (ImageJ).

Statistical analysis

All data are represented as mean±standard error of the mean. Comparisons of data from the different groups were performed with one-way analysis of variance (PASW Statistics version 18, SPSS, Inc., Chicago, IL, USA). Differences with P-values less than 0.05 were considered to be statistically significant. Each "n" value refers to the number of separate experiments conducted.

Results

RVS normalized the levels of CLC-related serologic parameters altered by BDL

To evaluate the protective effect of RVS in a rat model of BDL-induced CLC, quality of life (QOL)-related general conditions and liver functions were measured in terms of body weight, liver weight, and serologic parameters, such as serum tBil, dBil, AST, and ALT levels (Table 1). Our study revealed that 28 days of RVS administration failed to attenuate CLC-associated QOL deterioration, demonstrating that the loss of body weight induced by BDL was unchanged by RVS. Furthermore, RVS could not normalize the increase of liver weight, associated with the progression of CLC. Notably, tBil and dBil, serum markers of obstructive jaundice, and AST and ALT, serum markers of liver function, were elevated by BDL. The levels of these markers were significantly decreased by RVS treatment on POD 14. This indicated treatment with RVS before and after BDL protects against CLC-associated liver functional damage induced 14 days after BDL.

RVS attenuated CLC-associated histopathological alteration induced by BDL

A representative image of H&E-stained liver tissues, in contrast to normal rat liver morphology is shown in Fig. 1A and D. BDL caused severe histopathological changes such as steatosis, inflammatory cell infiltration (indicated by black arrows), and disarrangement of hepatic cords (Fig. 1B, E). Besides the disruption of tissue architecture, liver fibrosis was identified with fiber extension, large fibrous septa formation, and pseudo-lobe separation. However, these BDL-induced alterations decreased remarkably in the liver sections of rats that received RVS for 14 days before and after treatment (Fig. 1C, F). This indicated that RVS might prevent or resolve CLC-related histologic alterations in the liver.

RVS attenuated CLC-associated ECM deposition induced by BDL

To evaluate the degree of liver fibrosis on POD 14 in different groups, the extent of ECM deposition was studied through Masson's trichrome staining. As shown in representative images (Fig. 2A–C) and quantitative graphs for fibrotic area (Fig. 2G), the liver tissue of BDL group displayed a large area of ECM deposition, whereas that of BDL+RVS group showed markedly diminished area (89,922±38,721 vs. 342,536±97,302, P<0.001). Fibrosis degree (Fig. 2H), which was quantified by the modification of Knodell HAI criteria, was also increased in the BDL group compared to that in the SHAM group. However, the fibrosis degree of BDL+RVS group remarkably decreased when compared to that of the BDL group (2.7±0.50 vs. 4.42±0.78, P<0.001). Based on the notion that COL1 is the dominant constituent of ECM, we performed distributional (Fig. 2D–F) and semi-quantitative assessment (Fig. 2I, J) of COL1 in the livers of different groups. Compared to the SHAM group, the amount of COL1 in the liver tissue and tissue homogenates of BDL group markedly increased. The hepatic deposition of COL1 significantly decreased morphologically and semi-quantitatively in the BDL+RVS group compared with that in the BDL group (0.41±0.03 vs. 0.94±0.08, P<0.001). These results revealed that RVS might be useful in preventing or resolving liver fibrosis due to CLC.

RVS inhibited myofibroblast activation induced by BDL

As ECM is mainly synthesized by interstitial myofibroblasts, we tested whether the antifibrotic effects of RVS might be due to the inhibition of myofibroblast activation. For this purpose, IHC for α-SMA, a well-known marker of activated myofibroblast, was performed using liver tissue from different groups. In the SHAM group, α-SMA–immunopositive cells were hardly observed in liver parenchyma as well as in the portal areas (Fig. 3A). In the BDL group (Fig. 3B), numerous α-SMA–positive myofibroblasts were observed in the liver around the dilated ducts in the portal areas. However, the amount of these cells markedly decreased in the liver tissue of BDL+RVS group (Fig. 3C). Immunoblots also revealed that the levels of α-SMA and vimentin, another well-known marker of myofibroblast, dramatically increased in the BDL group compared with those in SHAM group (1.54±0.07 vs. 0.96±0.03 and 1.73±0.08 vs. 0.57±0.08, respectively, P<0.001). These levels were significantly decreased by the 28-day treatment with RVS (1.14±0.08 and 0.97±0.17, P<0.01 vs. BDL) (Fig. 3D–F). These findings indicated that the antifibrotic effect of RVS might be, at least partly, due to the inhibition of hepatic myofibroblast activation.

RVS inhibited profibrotic Smad3 signaling by Smad7 upregulation

Smad3 signaling is a key pathway leading to liver fibrosis upon stimulation by TGF-β, a major profibrotic cytokine that derived from various sources. Therefore, we investigated the mechanisms by which RVS attenuates BDL-induced CLC by examining the signaling pathway of Smad3 and its inhibitory regulator Smad7. We demonstrated that BDL group exhibited a marked upregulation of p-Smad3/Smad3 ratio (1.74±0.07 vs. 0.79±0.12, P<0.001) as well as a decreased level of Smad7 compared with SHAM group (0.37±0.12 vs. 0.6±0.03, P<0.001) (Fig. 4A–C). Notably, BDL+RVS group showed a significant reduction of p-Smad3 and an increase of Smad7 levels compared with the BDL group (1.74±0.07 vs. 0.67±0.1 and 1.71±0.07 vs. 0.37±0.12, P<0.001). This indicated that the inhibitory effect of RVS on myofibroblast activation might be due to the downregulation of Smad3 and reciprocal upregulation of Smad7 in liver tissue.

Discussion

Clinical studies and studies on animal models have been carried out to analyze the effects of administration of various synthetic drugs on liver fibrosis associated with or without CLC [28 29]. To date, however, these studies were not able to suggest definitive solutions regarding the beneficial or hazardous effect of therapeutic usage [30 31]. On the other hand, many traditional medicines and their natural products in Asian countries are known to be relatively low priced and effective resources for drug development, and identified with very little noxious effects in clinical situations involving hepatobiliary diseases [32]. It seems that the benefits far outweigh the potential risks, such as poisoning, nephrotoxicity, and acute hepatotoxicity, to the patient [33 34]. Thus, the therapeutic screening of natural plant extracts in this situation may be reasonable.

RVS, which has been used for thousands of years in Asian countries, is one of the remedies against liver injuries. RVS is a tree species of genus Toxicodendron belonging to the family Anacardiaceae and is grown in regions of China and Korea [35 36]. In Korea, RVS has been used as a therapeutic for digestive problems such as gastritis and abdominal masses since the ancient times [37]. RVS has also been used as a food additive. However, there is lack of scientific evidence proving these health benefits of RVS. Recently, a body of in vitro studies for RVS has emerged to reveal its potential antibacterial, antimicrobial, antirheumatoid, anti-inflammatory, antioxidant, antiaggregation, anticancer, and neuroprotective activities [38 39 40 41 42]. The effects of RVS on these entities in hepatobiliary diseases have been demonstrated by few approaches. RVS has been shown to suppress aflatoxin B1-induced increase in serum levels of ALT, alkaline phosphatase, and lactate dehydrogenase, prevent malondialdehyde formation, and inhibit the decrease in the levels of glutathione and superoxide dismutase in a mouse model [43]. In another study, RVS protected against liver damage through the inhibition of radical scavenging ability [44]. A study performed by Park et al. [45] proposed for the first time that methanol and ethyl acetate extract of RVS and two active compounds of RVS, sulfuretin and fustin, have a protective effect in experimental models of CLC. According to their reports, these compounds exerted hepatoprotective effects via the augmentation of the liver antioxidant defense system. Herein, we suggested the beneficial effects of RVS on CLC using different approaches.

Unlike in the study by Choi et al. [43], we focused on myofibroblast activation and its master signaling regulator, TGF-β/Smad pathway, possibly involved in the CLC pathogenesis. In this study, we demonstrated that BDL markedly elevated the levels of AST, ALT, tBil, and dBil, all of which were significantly attenuated by the 28-day treatment with RVS (2 mg/kg/day). We also observed the protection of liver histoarchitecture and inhibition of excessive deposition of ECM by RVS treatment. We observed that RVS inhibited BDL-induced proliferation and activation of interstitial myofibroblast, and these effects were strongly associated with the inactivation of Smad3 and reciprocal upregulation of Smad7.

However, we cannot rule out the possibility that RVS might exert protective effects on CLC by another mechanism. In fact, numerous factors that can be possible targets of RVS exist in the pathogenesis of CLC-induced liver fibrosis. All hepatic parenchymal cells undergo specific changes in the progression towards liver fibrosis. For example, the hepatocytes are injured and they undergo apoptosis and eventually necrosis [46 47]. The endothelial cells in sinusoidal capillary undergo a loss of fenestrae and intercellular integrity [48]. The Kupffer cells, which are the resident macrophages in the liver, activate and secrete various chemokines and cytokines [49 50]. The lymphocytes infiltrate the damaged liver and contribute to the inflammatory process. Finally, the quiescent HSC are activated to produce ECM [51 52]. Thus, based on the biological properties of RVS such as anti-apoptotic, angioprotective, anti-inflammatory, and antifibrotic effects, it was suggested that RVS might exert beneficial effects on CLC by multifactorial mechanisms. Therefore, by using single compounds within RVS, approaches for unveiling other therapeutic mechanisms and specific molecular targets might be needed in the context of protective effects of RVS on CLC.

Fig. 1

Protective effect of Rhus verniciflua Stokes (RVS) on bile duct ligation (BDL)–induced hepatic parenchymal injury. Rats (n=12 in each group) were pretreated with RVS (2 mg/kg) for 14 days, followed by BDL operation with RVS (2 mg/kg) for additional 14 days. Sham-surgery (SHAM) group underwent the same procedures except the actual ligation of the common bile duct. BDL group was administered distilled water as a vehicle. Representative photomicrographs are H&E stained tissue sections of SHAM (A, D), BDL (B, E), and BDL with RVS-treatment (BDL+RVS) groups (C, F) with low (A–C) and high magnification (D–F). The black arrows indicates infiltrated inflammatory cells. Scale bars=100 µm.

Fig. 2

Attenuation of bile duct ligation (BDL)–induced hepatic interstitial fibrosis by Rhus verniciflua Stokes (RVS) treatment. Rats (n=12 in each group) were pretreated with RVS (2 mg/kg) for 14 days, followed by BDL operation with RVS (2 mg/kg) for additional 14 days. Sham-surgery (SHAM) group underwent the same procedures except the actual ligation of the common bile duct. BDL group was administered distilled water as a vehicle. Representative photomicrographs in upper panel are Masson's trichrome-stained tissue sections of SHAM (A), BDL (B), and BDL with RVS-treatment (BDL+RVS) groups (C). Scale bar=100 µm (A–C). Photomicrographs in the lower panel are fluorescent images captured under laser confocal microscope, showing collagen-I (COL1) immunoreactivities (appeared red) in liver tissue sections of SHAM (D), BDL (E), and BDL+RVS groups (F). Scale bar=100 µm (D–F). Fibrotic area (G) was measured by the averaged area of blue pixels within each of the Masson's trichrome-stained liver tissue. The degree of fibrosis (H) was graded according to the modification of Knodell histology activity index using Masson's trichrome-stained liver sections. The amount of COL1 in liver homogenates of each group was assessed by immunoblots, and the resulting representative blot images (I) and quantitative graphs (J) are shown. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control (n=5; ^*P<0.05 and ^***P<0.001 compared with the SHAM group; ^###P<0.001 compared with the BDL group). Data in all graphs are expressed as the mean±SD.

Fig. 3

Attenuation of bile duct ligation (BDL)–induced myofibroblast activation by Rhus verniciflua Stokes (RVS) treatment. Rats (n=12 in each group) were pretreated with RVS (2 mg/kg) for 14 days followed by BDL operation with RVS (2 mg/kg) for additional 14 days. Sham-surgery (SHAM) group underwent the same procedures except the actual ligation of the common bile duct. BDL group was administered distilled water as a vehicle. Representative images of immunohistochemistry staining for α-smooth muscle actin (α-SMA; appeared brown) in the liver tissue sections of SHAM (A), BDL (B), and BDL with RVS-treatment (BDL+RVS) groups (C) are shown. Nuclei (appeared purple) were counterstained by hematoxylin. Scale bar=100 µm. The amount of α-SMA and vimentin in liver homogenates was assessed by immunoblots. The representative blot images (D) and quantitative graphs revealing α-SMA (E) and vimentin (F) expression are shown. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control (n=5; ^*P<0.05 and ^***P<0.001 compared with the SHAM group; ^##P<0.01 compared with the BDL group). Data in both graphs are expressed as the mean±SD.

Fig. 4

Effects of Rhus verniciflua Stokes (RVS) on bile duct ligation (BDL)–induced alterations in p-Smad3/Smad3 ratio and amount of Smad7 in liver homogenates. Rats (n=12 in each group) were pretreated with RVS (2 mg/kg) for 14 days followed by BDL operation with RVS (BDL+RVS, 2 mg/kg) for additional 14 days. Sham-surgery (SHAM) group underwent the same procedures except the actual ligation of the common bile duct. BDL group was administered distilled water as a vehicle. The amount of p-Smad3, Smad3, and Smad7 in the liver homogenates of different groups was assessed by immunoblots. The representative blot images (A) and quantitative graphs revealing p-Smad3/Smad3 ratio (B) and Smad7 (C) expression are shown. Smad3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as loading controls in panels (B) and (C), respectively (n=5; ^*P<0.05 and ^***P<0.001 compared with the SHAM group; ^###P<0.01 compared with the BDL group). Data in both graphs are expressed as the mean±SD.

Table 1

Effect of RVS on BDL-induced alterations in physical and serological parameters

Parameter	SHAM	BDL	BDL+RVS
Body weight (g)	390±21.7	328±17.2^c)	338±38.2^a)
Liver weight (g)	13.1±1.4	20.4±1.3^c)	18.6±1.9^c)
Liver/Body weight (%)	3.4±0.3	5.9±0.9^c)	5.6±0.7^c)
Total bilirubin (mg/dl)	0.4±0.1	9.9±0.8^c)	6.6±1.9^b),d)
Direct bilirubin (mg/dl)	0.1±0.0	9.8±1.2^c)	6.5±1.0^c),d)
AST (U/l)	50.3±5.5	500.7±76.0^c)	175.7±42.6^b),e)
ALT (U/l)	29.0±1.7	167.7±31.5^c)	67.7±35.3^b),d)

Values are presented as the mean±SD. RVS, Rhus verniciflua Stokes; BDL, bile duct ligation; SHAM, sham-surgery; BDL+RVS, BDL with RVS-treatment; AST, aspartate transaminase; ALT, alanine transaminase. ^a)P<0.05, ^b)P<0.01, and ^c)P<0.001 compared with the SHAM group. ^d)P<0.05 and ^e)P<0.01 compared with the BDL group.

Acknowledgements

This study was supported by the Development of Forest Science and Technology (grant numbers S111414L030100) and the Korea Research Foundation (grant numbers NRF-2014R1A1A403005726 and -2016R1C1B2012351).

References

1. FeldJJHeathcoteEJEpidemiology of autoimmune liver diseaseJ Gastroenterol Hepatol20031811181128[PubMed][Google Scholar]
2. IredaleJPCirrhosis: new research provides a basis for rational and targeted treatmentsBMJ2003327143147[PubMed][Google Scholar]
3. SchuppanDRuehlMSomasundaramRHahnEGMatrix as a modulator of hepatic fibrogenesisSemin Liver Dis200121351372[PubMed][Google Scholar]
4. BatallerRBrennerDALiver fibrosisJ Clin Invest2005115209218[PubMed][Google Scholar]
5. FriedmanSLMechanisms of hepatic fibrogenesisGastroenterology200813416551669[PubMed][Google Scholar]
6. SasakiTOhtaSKamogawaAShinodaMProtective effects of various Chinese traditional medicines against experimental cholestasisChem Pharm Bull (Tokyo)199038513516[PubMed][Google Scholar]
7. DooleySHamzaviJBreitkopfKWiercinskaESaidHMLorenzenJTen DijkePGressnerAMSmad7 prevents activation of hepatic stellate cells and liver fibrosis in ratsGastroenterology2003125178191[PubMed][Google Scholar]
8. DooleySHamzaviJCiuclanLGodoyPIlkavetsIEhnertSUeberhamEGebhardtRKanzlerSGeierABreitkopfKWengHMertensPRHepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damageGastroenterology2008135642659[PubMed][Google Scholar]
9. Meindl-BeinkerNMDooleySTransforming growth factor-beta and hepatocyte transdifferentiation in liver fibrogenesisJ Gastroenterol Hepatol200823Suppl 1S122S127[PubMed][Google Scholar]
10. Kershenobich StalnikowitzDWeissbrodABLiver fibrosis and inflammation: a reviewAnn Hepatol20032159163[PubMed][Google Scholar]
11. SzaboGMandrekarPDolganiucAInnate immune response and hepatic inflammationSemin Liver Dis200727339350[PubMed][Google Scholar]
12. LuperSA review of plants used in the treatment of liver disease: part 1Altern Med Rev19983410421[PubMed][Google Scholar]
13. KittsDDLimKTAntitumorigenic and cytotoxic properties of an ethanol extract derived from Rhus verniciflua Stokes (RVS)J Toxicol Environ Health A200164357371[PubMed][Google Scholar]
14. LimKTHuCKittsDDAntioxidant activity of a Rhus verniciflua Stokes ethanol extractFood Chem Toxicol200139229237[PubMed][Google Scholar]
15. JeonWKKimJHLeeHWKoBSKimHKEffects of Rhus verniciflua Stokes (RVS) extract on diet-induced obesity in C57BL/6 mouseKorean J Pharmacogn200334339343[Google Scholar]
16. KimMJChoiWCBarshinikovAMKobayashiAAnticancer and antioxidant activity of allergen-removed extract in Rhus verniciflua StokesKorean J Med Crop Sci200210288293[Google Scholar]
17. KimITParkYMShinKMHaJChoiJJungHJParkHJLeeKTAnti-inflammatory and anti-nociceptive effects of the extract from Kalopanax pictus, Pueraria thunbergiana and Rhus vernicifluaJ Ethnopharmacol200494165173[PubMed][Google Scholar]
18. ParkKYJungGOLeeKTChoiJChoiMYKimGTJungHJParkHJAntimutagenic activity of flavonoids from the heartwood of Rhus vernicifluaJ Ethnopharmacol2004907379[PubMed][Google Scholar]
19. KoJHLeeSJLimKTRhus verniciflua Stokes glycoprotein (36kDa) has protective activity on carbon tetrachloride-induced liver injury in miceEnviron Toxicol Pharmacol200622814[PubMed][Google Scholar]
20. Szuster-CiesielskaAMizerska-DudkaMDanilukJKandefer-SzerszeńMButein inhibits ethanol-induced activation of liver stellate cells through TGF-beta, NFkappaB, p38, and JNK signaling pathways and inhibition of oxidative stressJ Gastroenterol201348222237[PubMed][Google Scholar]
21. HanQBSongJZQiaoCFWongLXuHXPreparative separation of gambogic acid and its C-2 epimer using recycling high-speed counter-current chromatographyJ Chromatogr A20061127298301[PubMed][Google Scholar]
22. KimSAKimSHKimISLeeDDongMSNaCSNhiemNXYooHHSimultaneous determination of bioactive phenolic compounds in the stem extract of Rhus verniciflua stokes by high performance liquid chromatographyFood Chem201314138133819[PubMed][Google Scholar]
23. TagCGSauer-LehnenSWeiskirchenSBorkham-KamphorstETolbaRHTackeFWeiskirchenRBile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasisJ Vis Exp20159652438[Google Scholar]
24. FischerAHJacobsonKARoseJZellerRHematoxylin and eosin staining of tissue and cell sectionsCSH Protoc20082008pdb.prot4986[PubMed][Google Scholar]
25. GoldnerJA modification of the masson trichrome technique for routine laboratory purposesAm J Pathol193814237243[PubMed][Google Scholar]
26. KnodellRGIshakKGBlackWCChenTSCraigRKaplowitzNKiernanTWWollmanJFormulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisHepatology19811431435[PubMed][Google Scholar]
27. KimJHYuKSJeongJHLeeNSLeeJHJeongYGYooYCHanSYAll-trans-retinoic acid rescues neurons after global ischemia by attenuating neuroinflammatory reactionsNeurochem Res20133826042615[PubMed][Google Scholar]
28. RigatoICravatariMAvelliniCPonteECrocèSLTiribelliCDrug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1Nat Clin Pract Gastroenterol Hepatol20074403408[PubMed][Google Scholar]
29. ShahBShahGAntifibrotic effect of heparin on liver fibrosis model in ratsWorld J Gastrointest Pharmacol Ther201238692[PubMed][Google Scholar]
30. ScottSThompsonJAdverse drug reactionsAnaesth Intensive Care Med201415245249[Google Scholar]
31. KashawVNemaAKAgarwalAHepatoprotective prospective of herbal drugs and their vesicular carriers: a reviewInt J Res Pharm Biomed Sci20112360374[Google Scholar]
32. ZhangASunHWangXRecent advances in natural products from plants for treatment of liver diseasesEur J Med Chem201363570577[PubMed][Google Scholar]
33. BalandrinMFKlockeJAWurteleESBollingerWHNatural plant chemicals: sources of industrial and medicinal materialsScience198522811541160[PubMed][Google Scholar]
34. SrivastavaJLambertJVietmeyerNMedicinal plants: an expanding role in development. World Bank Technical Paper 320Washington, DCWorld Bank Publications1996
35. KimTJKorean resource plantsVol. IISeoulSeoul National University Press1996292297
36. HongDHHanSBLeeCWParkSHJeonYJKimMJKwakSSKimHMCytotoxicity of urushiols isolated from sap of Korean lacquer tree (Rhus vernicifera Stokes)Arch Pharm Res199922638641[PubMed][Google Scholar]
37. NambaTColoured illustrations of Wakan-YakuOsakaHoikusha Publishing Co.1980
38. LeeJCKimJLimKTYangMSJangYSEthanol eluted extract of Rhus verniciflua Stokes showed both antioxidant and cytotoxic effects on mouse thymocytes depending on the dose and time of the treatmentBMB Rep200134250258[Google Scholar]
39. LeeJCLimKTScreening of antioxidant and antimicrobial effects from Rhus verniciflua Stokes (RVS) ethanolic extractFood Sci Biotechnol20009139145[Google Scholar]
40. LeeJDHuhJEJeonGYangHRWooHSChoiDYParkDSFlavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo modelsInt Immunopharmacol20099268276[PubMed][Google Scholar]
41. LeeJCJungHYLimKTEffects of Rhus verniciflua Stokes (RVS) on the plasma level of cholesterol and tumor growth in mouseJ Toxicol Public Health199915169175[Google Scholar]
42. ChoNChoiJHYangHJeongEJLeeKYKimYCSungSHNeuroprotective and anti-inflammatory effects of flavonoids isolated from Rhus verniciflua in neuronal HT22 and microglial BV2 cell linesFood Chem Toxicol20125019401945[PubMed][Google Scholar]
43. ChoiKCChungWTKwonJKJangYSYuJYParkSMLeeJCChemoprevention of a flavonoid fraction from Rhus verniciflua Stokes on aflatoxin B1-induced hepatic damage in miceJ Appl Toxicol201131150156[PubMed][Google Scholar]
44. LeeJCLimKTJangYSIdentification of Rhus verniciflua Stokes compounds that exhibit free radical scavenging and anti-apoptotic propertiesBiochim Biophys Acta20021570181191[PubMed][Google Scholar]
45. ParkHJLeeKTParkKYHanGYJungMHChoiJProtective mechanism of flavonoids isolated from Rhus verniciflua on the biliary liver fibrosis in ratKorean J Life Sci200212332339[Google Scholar]
46. FaubionWAGuicciardiMEMiyoshiHBronkSFRobertsPJSvingenPAKaufmannSHGoresGJToxic bile salts induce rodent hepatocyte apoptosis via direct activation of FasJ Clin Invest1999103137145[PubMed][Google Scholar]
47. PatelTBronkSFGoresGJIncreases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytesJ Clin Invest19949421832192[PubMed][Google Scholar]
48. FernándezMSemelaDBruixJColleIPinzaniMBoschJAngiogenesis in liver diseaseJ Hepatol200950604620[PubMed][Google Scholar]
49. ZavadilJBottingerEPTGF-beta and epithelial-to-mesenchymal transitionsOncogene20052457645774[PubMed][Google Scholar]
50. Hernandez-GeaVFriedmanSLPathogenesis of liver fibrosisAnnu Rev Pathol20116425456[PubMed][Google Scholar]
51. MaherJJInteractions between hepatic stellate cells and the immune systemSemin Liver Dis200121417426[PubMed][Google Scholar]
52. MehalWZFriedmanSLThe role of inflammation and immunity in the pathogenesis of liver fibrosisGershwinMEVierlingJMMannsMPLiver ImmunologyTotowa, NJHumana Press2007111121